NewAmsterdam Pharma Company N.V. (NAMS)
NEUTRALFundamental
33
Precio
$27.19
Capitalización Bursátil
$3.14B
Parte 1 · Cuánto vale la empresa
Resumen
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$7M
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-260M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$-148M
Patrimonio Neto Total
$683M
Pasivo Total
$86M
Ratio de Liquidez
9.03
Cobertura de Intereses
-
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$30.63
Precio Actual
$27.19
Margen de Seguridad
+11.2%
Rango de Valor Justo
$19.91 - $41.34
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-29.8%
Ratio P/B
5.08
P/FCF
-
Margen Bruto
-
ROIC
-30.6%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-30.6%
WACC
8.0%
ROIC − WACC
-38.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (6)
- EPS shows upward trend
- Price CAGR 23.38%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 91% Buy
Fallido (11)
- ROIC -30.6%
- P/B Ratio 5.08
- Operating Margin -3432.2%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -38.3%
- Earnings Surprise avg -23.2%
- Share Dilution 25.6%
- Net Margin Trend -3644.2% vs -258.9%
- Piotroski F-Score 3/9
No disponible (10)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President & Executive Director | 69 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 71 |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | 51 |
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for NAMS, sourced from Markets Gazette.